ARTICLE | Company News
Micrologix other research news
July 26, 2004 7:00 AM UTC
In an in vitro model of HCV infection, MBI-3253 showed additive and synergistic effects when combined with ribavirin or interferon alpha. No cellular toxicity was reported at high drug concentrations....